Evidence map›Paper›PMID 22728222›Full record

ArticleVaccine2012

Antibody response to the central unglycosylated region of the respiratory syncytial virus attachment protein in mice.

Yoshihiko Murata, Seana C Catherman

Open access · greenAbstract read
In one paragraph

Article in Vaccine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Rapid replacement of human respiratory syncytial virus A with the ON1 genotype having 72 nucleotide duplication in G gene.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2014
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Yoshihiko MurataDivision of Infectious Diseases, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA. Yoshihiko_Murata@urmc.rochester.edu
Seana C Catherman
Rochester General Hospital · US

Funding

Humoral Immune Response to Neutralizing Epitopes of the RSV F ProteinR56AI091731 · NIAID · UNIVERSITY OF ROCHESTER · PI JARDETZKY, THEODORE S, MURATA, YOSHIHIKO · 2011 to 2011
$561k
RSV Vaccine Development Based on HPV Virus-Like ParticlesR21AI076781 · NIAID · UNIVERSITY OF ROCHESTER · PI MURATA, YOSHIHIKO · 2008 to 2009
$420k
NIAID NIH HHS R21 AI076781NIAID NIH HHS R56 AI091731
6 · The paper itself

Abstract

We examined the humoral immune response to the unglycosylated central region of the respiratory syncytial virus (RSV) attachment (G) protein in mice following intranasal challenge at day 0 (primary) and day 21 (secondary) with subtype A (A2 strain) or B (B1 strain) RSV preparations. Our serological screening reagents included bacterially derived glutathione S-transferase (GST) fusion proteins, each bearing a portion of the RSV G central core (CC; residues 151-190), proximal central core (PCC; residues 151-172), and the distal central core (DCC; residues 173-190) and purified RSV G proteins from subtype A and B viruses. Convalescent sera collected on day 21 following primary RSV infection bore robust IgG response primarily against the homosubtypic RSV G DCC with relatively modest antigen affinity/avidity as demonstrated by brief incubation with 6M urea. In contrast, sera collected on day 42 following secondary homosubtypic RSV infection bore IgG titers of higher magnitudes and antigen affinity/avidity against the homosubtypic RSV G CC, PCC, and/or the DCC regions and full-length RSV G protein but not against the heterosubtypic RSV G protein or recombinant CC subdomains. In contrast, heterosubtypic secondary RSV infection elicits a broad array of IgG responses with titers of varying magnitudes to homo- and heterosubtypic RSV G CC regions as well as to purified F, Ga, and Gb proteins with the notable exception of minimal response to the RSV G DCC domain associated with the secondary RSV challenge. Our results have implications for RSV G-based serological assays as well as prophylactic immunotherapy and RSV vaccine development.

Indexed as

Amino Acid SequenceAnimalsAntibodies, ViralCell LineFemaleHumansLungMiceMice, Inbred BALB CMolecular Sequence DataRespiratory Syncytial VirusesRespiratory Syncytial Virus InfectionsViral Envelope ProteinsVirus ReplicationAntibodies, ViralViral Envelope Proteins

Identifiers

PMID22728222
PMCPMC3401318
OpenAlexW1996208929

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.